Vestal Point Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Vestal Point Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,850,000	Closed	-$37.2M	–	82
2026 Q1	$37.2M	Sell	1,850,000 -40,000	-2%	-$645K	1.04%	33
2025 Q4	$30.5M	Buy	1,890,000 +1,140,000	+152%	+$15.1M	1.04%	31
2025 Q3	$9.13M	Sell	750,000 -3,925,000	-84%	-$54.2M	0.41%	53
2025 Q2	$52.9M	Sell	4,675,000 -76,292	-2%	-$933K	2.78%	10
2025 Q1	$54.8M	Sell	4,751,292 -18,708	-0.4%	-$191K	3.92%	6
2024 Q4	$40.4M	Buy	4,770,000 +770,000	+19%	+$7.97M	2.4%	14
2024 Q3	$46.3M	Buy	4,000,000 +1,700,000	+74%	+$21.4M	3.51%	7
2024 Q2	$27.1M	Buy	2,300,000 +1,645,000	+251%	+$19.2M	2.02%	14
2024 Q1	$7.77M	Buy	+655,000	New	+$8.73M	0.64%	33

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vestal Point Capital's KALV Position: Q2 2026 in Review

Vestal Point Capital sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 1,850,000 shares — an estimated $37.2M sold.

Vestal Point Capital first reported a position in KALV in Q1 2024 and held it in 9 quarters. The position peaked at $54.8M in Q1 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Vestal Point Capital reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Vestal Point Capital sold 1,850,000 KalVista Pharmaceuticals shares in Q2 2026, an estimated $37.2M.
Vestal Point Capital first reported a position in KalVista Pharmaceuticals in Q1 2024 and held it in 9 quarters.
Vestal Point Capital's KalVista Pharmaceuticals position peaked at $54.8M in Q1 2025.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.